Publications

Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): Emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections. by Johnson DM, Biedenbach D and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 43 (1): 49-60

Quality control guidelines for tiamulin (Denagard^TM) susceptibility testing. by Walter D, Pfaller MA and Jones RN published in Proceedings of the 17th IPVS Congress, Ames, IA June 2-5, 2002; Vol 2: 256

Interpretive criteria for tiamulin (Denagard^TM) susceptibility testing. by Walter D, Jones RN, Pfaller MA published in Proceedings of the 17th IPVS Congress, Ames, IA 2002; Vol 2: 80

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. by Pfaller MA, Messer SA, Hollis RJ, Jones RN and Diekema DJ published in Antimicrob. Agents Chemother. 2002; 46 (6): 1723-1727

Antimicrobial susceptibilities of H. influenzae and M. catarrhalis causing lower respiratory tract infections: SENTRY Antimicrobial Surveillance Program, Europe 2000. Abstr. P1109. by Loza E, Canton R, Morosini MI, Jones RN, Baquero F and The SENTRY Participants Group published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1):250-251

Validation of commercial dry-form panels (Sensititre) for the susceptibility testing of AZD2563, a new long-Acting Oxazolidinone. Abstr. #P1045. by Jones RN, Anderegg T, Biedenbach DJ and Rhomberg P published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1): 233

Intermethod agreement and preliminary quality control (QC) guidelines for susceptibility testing AZD2563 by disk diffusion and MIC methods. by Anderegg T and Jones RN published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1): 232-233

Epidemiology of antibiotic resistance of bacterial pathogens from intensive care units: The SENTRY Surveillance Program in Europe 2000. by Rodriguez-Villalobos H, Jones RN, Struelens MJ published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1):196-197

In vitro activity of meropenem, imipenem, piperacillin/tazobactam, ciprofloxacin, amikacin, and cefepime against P. aeruginosa and A. baumannii isolated from Brazilian intensive care units: MYSTIC Study Group (Brazil 2001). by Mendes C, Kiffer C, Oplustil C, Sinto S, Turner P, Jones RN and Hsiung A published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1): 165

Tracking Streptococcus pneumoniae isolates with decreased antimicrobial susceptibility by MIC distribution analysis: SENTRY, Europe 1997-2000. Abstr. #P456 by Canton R, Loza E, Morosini MI, Voerhoef J and Jones RN published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1):75

Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: Report from the SENTRY Antimicrobial Surveillance Program (1998-1999) including an in vitro evaluation of BMS284756. by Bell J, Turnidge J, Jones RN and SENTRY Regional Participants Group published in Int. J. Antimicrob. Agents 2002; 19 (2): 125-132

Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS284756 (T-3811) tested against non-fermentative Gram-negative bacilli. by Howard W, Biedenbach DJ, Jones RN published in Clin. Microbiol. Infect. 2002; 8: 340-344

Comparative antimicrobial spectrum and activity of BMS284756 (T-3811; a desfluoroquinolone) tested against an international collection of staphylococci and enterococci, including in vitro test development and intermethod comparisons. by Pfaller MA, Jones RN, Biedenbach DJ, Beach ML published in J. Chemother. 2002; 14 (1): 13-18

Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia. by Nicholson SC, Naughton BJ, Webb CD. published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 117-125

Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. by Nicholson SC, High KP, Gothelf S and Webb CD published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 109-116

Oral gatifloxacin in outpatient community-acquired pneumonia: Results from TeqCES, a community-based, open-label, multicenter study. by Gotfried M, Quinn T, Gothelf S, Wikler MA, Webb CD and Nicholson SC. published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 85-91

Safety and efficacy of gatifloxacin in community-acquired pneumonia: Rationale for the Tequin Clinical Experience Study (TeqCES). by Mandell LA published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 65-67

Emerging antimicrobial resistances among Proteus mirabilis in Europe: Report from the MYSTIC Program (1997-2001). by Mutnick AH, Turner PJ and Jones RN published in J. Chemother. 2002; 14 (3): 253-258

Antimicrobial susceptibility patterns of Beta-hemolytic and viridans group streptococci: Report from the SENTRY Antimicrobial Surveillance Program (1997-2000). by Gordon KA, Beach ML, Biedenbach DJ, Jones RN, Rhomberg PR and Mutnick AH published in Diagn. Microbiol. Infect. Dis. 2002; 43 (2): 157-162

Spectrum and potency evaluation of a new oxazolidinone, linezolid: Report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. by Mutnick AH, Biedenbach DJ, Turnidge JD and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 43 (1): 65-73

First description of Klebsiella pneumoniae harboring CTX-M beta-lactamases (CTX-M-14 and CTX-M-3) in Taiwan. by Yu WL, Winokur PL, Von Stein DL, Pfaller MA, Wang JH and Jones RN published in Antimicrob Agents Chemother 2002; 46 (4): 1098-1100

Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan. by Yu WL, Pfaller MA, Winokur PL and Jones RN published in Emerg. Infect. Dis. 2002; 8 (5): 522-524

In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. by Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 42 (2): 145-147

Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. by Pfaller MA, Diekema DJ, Jones RN, Messer SA and Hollis RJ published in J. Clin. Microbiol. 2002; 40 (3): 852-856

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. by Pfaller MA, Messer SA, Hollis RJ and Jones RN published in Antimicrob. Agents Chemother. 2002; 46 (4): 1032-1037

Antimicrobial susceptibility of inducible AmpC β-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. by Pfaller MA and Jones RN published in Int. J. Antimicrob. Agents 2002; 19 (5): 383-388

Tiamulin activity against fastidious and nonfastidious veterinary and human bacterial isolates: Initial development of in vitro susceptibility test methods. by Jones RN, Pfaller MA, Rhomberg PR and Walter DH. published in J. Clin. Microbiol. 2002; 40 (2): 461-465

In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual Gram-positive species. by Jones RN, Biedenbach DJ and Anderegg TR published in Diagn. Microbiol. Infect. Dis. 2002; 42 (2): 119-122

Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: Report from the SENTRY Antimicrobial Surveillance Program. by Jones RN, Della-Latta P, Lee LV and Biedenbach DJ published in Diagn. Microbiol. Infect. Dis. 2002; 42 (2): 137-139

Ciprofloxacin as broad-spectrum empiric therapy–are fluoroquinolones still viable monotherapeutic agents compared with β-lactams: Data from the MYSTIC Program (US) by Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2002; 42 (3): 213-215

BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Programme (2000). by Gordon KA, Pfaller MA and Jones RN. published in J. Antimicrob. Chemother. 2002; 49 (5): 851-855

Antimicrobial resistance in Gram-negative isolates from European intensive care units: Data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme. by Garcia-Rodriguez JA and Jones RN published in J. Chemother. 2002; 14 (1): 25-32

Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): Correlations of results from disk diffusion, Etest and reference dilution methods. by Deshpande LM, Fix AM, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 42 (4): 283-290

Molecular typing and antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium in Brazil. by Cereda RF, Gales AC, Silbert S, Jones RN and Sader HS published in Infect. Control. Hosp. Epidemiol. 2002; 23 (1): 19-22

Pharmacodynamics in the evaluation of drug regimens. by Bhavnani SM, Ambrose PG and Jones RN published in Ann. Pharmacother. 2002; 36 (3): 530-532

Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: Regional results from SENTRY Antimicrobial Surveillance Program (1998-99). by Bell JM, Turnidge JD, Gales AC, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 42 (3): 193-198

Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. by Ambrose PG, Owens RC, Jr., Garvey MJ, and Jones RN published in J. Antimicrob. Chemother. 2002; 49 (3): 445-453

Molecular Epidemiology of Inducible Macrolide Resistance in Staphylococcus aureus in the Western Pacific: Results from SENTRY Western Pacific Plus (WP+) 1998-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Quality Control Evaluation of BMS-284756 (T-3811ME) 5-mg Disk Diffusion (DD) and MIC Testing, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

In-vitro Activity of BMS-284756 (T-3811ME), a des-F(6)-Quinolone, Against Organisms Collected in the SENTRY (2000) European Susceptibility Study, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

BMS-284756 (T-3811ME) Susceptibility Test Comparisons and Development for More Than 30 Bacterial Species Using 3,328 Recent Clinical Isolates, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Extended Spectrum Beta-Lactamase (ESBL) Phenotypes In Enteric Bacilli from the Asia-Pacific Region: Report from the SENTRY Antimicrobial Surveillance Program, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Antifungal Activity of Posaconazole, Ravuconazole, and Voriconazole Compared to that of Itraconazole and Amphotericin B Against 239 Clinical Isolates of Aspergillus spp. and other Filamentous Fungi: Report from SENTRY Program, 2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Species Distribution and Antifungal Susceptibility (AFS) Patterns for Candida Bloodstream Isolates from the SENTRY Participants Group [Europe] 1999 – 2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Blood Stream Infections: SENTRY Antimicrobial Surveillance Program, 1997-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Trends in Antimicrobial Susceptibility of Bacterial Pathogens Isolated from Patients with Blood Stream Infections (BSI) in North America (NA): SENTRY Program, 1997-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Extreme Variations in Susceptibility (S) of P. aeruginosa (PSA) Among Hospitals in North America (NA), Latin America (LA), Europe (EU) and the Asia-Pacific (AP): Report from the SENTRY Antimicrobial Surveillance Program, 1997-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Frequency of Occurrence of Bacterial Pathogens in Bacteremic Infections and Antimicrobial Susceptibility From the SENTRY Surveillance Programme in Europe 2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Regional Variations and Trends in Antimicrobial Resistance Among E. faecalis (EF) and E. faecium (EFM) in the Global SENTRY Antimicrobial Surveillance Program (1997-2000), presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Trends in Antimicrobial Susceptibility of Bacterial Pathogens Isolated from Pediatric and Adult Patients with Blood Stream Infections in North America: SENTRY 1997-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois